The big pharma company AstraZeneca has forged a licensing pact worth $2 billion with the Chinese firm CSPC Pharmaceutical Group for access to an experimental small molecule treatment for dyslipidemia.
Artificial intelligence (AI) is now infiltrating core industries and according to Forbes, the market is expected to reach a value of $22.6 billion dollars by next year (2025). One area it is thriving ...
The partners are preparing for commercialization of the lung cancer drug limertinib as they await an approval decision from China’s National Drug Administration.